Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin versus donepezil in mild to moderate Alzheimer's disease
2012-004944-31Phase 3Completed
- Sponsor
- EVER Pharma
- Start
- Apr 2014
- Modality
- Small Molecules, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Cerebrolysin with donepezil (2 arms). Primary endpoints: Global risk-benefit non-inferiority, Combined primary safety and efficacy endpoints and 1 more. Started Apr 2014; status: completed.
02
Drugs
cerebrolysindonepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2012-004944-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004944-31.